Imaging classification of autosomal dominant polycystic kidney disease: A simple model for selecting patients for clinical trials

Journal of the American Society of Nephrology

Volumn 26, Issue 1, 2015, Pages 160-172

  Irazabal, María V ^a   Rangel, Laureano J ^a   Bergstralh, Eric J ^a   Osborn, Sara L ^a   Harmon, Amber J ^a   Sundsbak, Jamie L ^a   Bae, Kyongtae T ^b   Chapman, Arlene B ^c   Grantham, Jared J ^d   Mrug, Michal ^e   Hogan, Marie C ^a   El Zoghby, Ziad M ^a   Harris, Peter C ^a   Erickson, Bradley J ^a   King, Bernard F ^a   Torres, Vicente E ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^e University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHILD; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE CLASSIFICATION; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; INFANT; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; NEWBORN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PRIORITY JOURNAL; STEREOLOGY; AGE; AGED; CLINICAL TRIAL (TOPIC); DISEASE COURSE; IMAGE PROCESSING; KIDNEY; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; MORTALITY; PATHOLOGY; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; KIDNEY; KIDNEY FAILURE, CHRONIC; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PATIENT SELECTION; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84924196321     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013101138     Document Type: Article

References (33)

1. Torres VE, Harris PC, Pirson Y: Autosomal dominant polycystic kidney disease. Lancet 369: 1287-1301, 2007
2. Grantham JJ: Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 359: 1477-1485, 2008
3. Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr, Wetzel LH, Baumgarten DA, Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman GN, Meyers CM, Zhang X, Zhu F, Miller JP; CRISP Investigators: Volume progression in polycystic kidney disease. N Engl J Med 354: 2122-2130, 2006
4. Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D, Li J, King BF, Martin D, Wetzel LH, Lockhart ME, Harris PC, Moxey-Mims M, Flessner M, Bennett WM, Grantham JJ: Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 7: 479-486, 2012
5. Chapman AB, Torres VE, Perrone RD, Steinman TI, Bae KT, Miller JP, Miskulin DC, Rahbari Oskoui F, Masoumi A, Hogan MC, Winklhofer FT, Braun W, Thompson PA, Meyers CM, Kelleher C, Schrier RW: The HALT polycystic kidney disease trials: Design and implementation. Clin J Am Soc Nephrol 5: 102-109, 2010
6. Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, Horie S, Nutahara K, Ouyang J, Krasa HB, Czerwiec FS; TEMPOFormula and 156-05-002 Study Investigators: Tolvaptan in autosomal dominant polycystic kidney disease: Three years' experience. Clin J Am Soc Nephrol 6: 2499-2507, 2011
7. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators: Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367: 2407-2418, 2012
8. Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, Ene-Iordache B, Remuzzi G, Epstein FH: Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 68: 206-216, 2005
9. van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL, Dekker HM, de Man RA, Drenth JP: Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 137: 1661, e1-e2, 2009
10. Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, Kim B, King BF, Glockner J, Holmes DR 3rd, Rossetti S, Harris PC, LaRusso NF, Torres VE: Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 21: 1052-1061, 2010
11. Caroli A, Perico N, Perna A, Antiga L, Brambilla P, Pisani A, Visciano B, Imbriaco M, Messa P, Cerutti R, Dugo M, Cancian L, Buongiorno E, De Pascalis A, Gaspari F, Carrara F, Rubis N, Prandini S, Remuzzi A, Remuzzi G, Ruggenenti P; ALADIN study group: Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): A randomised, placebo-controlled, multicentre trial. Lancet 382: 1485-1495, 2013
12. Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wüthrich RP: Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 363: 820-829, 2010
13. Walz G, Budde K, Mannaa M, Nürnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Hörl WH, Obermüller N, Arns W, Pavenstädt H, Gaedeke J, Büchert M, May C, Gschaidmeier H, Kramer S, Eckardt KU: Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 363: 830-840, 2010
14. Perico N, Antiga L, Caroli A, Ruggenenti P, Fasolini G, Cafaro M, Ondei P, Rubis N, Diadei O, Gherardi G, Prandini S, Panozo A, Bravo RF, Carminati S, De Leon FR, Gaspari F, Cortinovis M, Motterlini N, Ene-Iordache B, Remuzzi A, Remuzzi G: Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol 21: 1031-1040, 2010
15. Bae KT, Grantham JJ: Imaging for the prognosis of autosomal dominant polycystic kidney disease. Nat Rev Nephrol 6: 96-106, 2010
16. Poggio ED, Rule AD, Tanchanco R, Arrigain S, Butler RS, Srinivas T, Stephany BR, Meyer KH, Nurko S, Fatica RA, Shoskes DA, Krishnamurthi V, Goldfarb DA, Gill I, Schreiber MJ Jr: Demographic and clinical characteristics associated with glomerular filtration rates in living kidney donors. Kidney Int 75: 1079-1087, 2009
17. Hateboer N, v Dijk MA, Bogdanova N, Coto E, Saggar-Malik AK, San Millan JL, Torra R, Breuning M, Ravine D: Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 353: 103-107, 1999
18. Harris PC, Bae KT, Rossetti S, Torres VE, Grantham JJ, Chapman AB, Guay-Woodford LM, King BF, Wetzel LH, Baumgarten DA, Kenney PJ, Consugar M, Klahr S, Bennett WM, Meyers CM, Zhang QJ, Thompson PA, Zhu F, Miller JP: Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 17: 3013-3019, 2006
19. Rossetti S, Kubly V, Consugar M, Hopp K, Roy S, Horsley S, Chauveau D, Rees L, Barratt TM, van't Hoff W, Niaudet WP, Torres VE, Harris PC: Incompletely penetrant PKD1 alleles associated with mild, homozygous and in utero onset polycystic kidney disease. Kidney Int 75: 848-855, 2009
20. Cornec-Le Gall E, Audrézet MP, Chen JM, Hourmant M, Morin MP, Perrichot R, Charasse C, Whebe B, Renaudineau E, Jousset P, Guillodo MP, Grall-Jezequel A, Saliou P, Férec C, Le Meur Y: Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol 24: 1006-1013, 2013
21. Hwang Y-H, Conklin J, Campbell K, He N, Wang K, Sundsbak JL, Heyer CM, Haider M, Harris PC, Pei Y: Hypomorphic PKD1 mutations are a common cause of mild ADPKD [Abstract]. J Am Soc Nephrol 23: 700A, 2012
22. Connor A, Lunt PW, Dolling C, Patel Y, Meredith AL, Gardner A, Hamilton NK, Dudley CR: Mosaicism in autosomal dominant polycystic kidney disease revealed by genetic testing to enable living related renal transplantation. Am J Transplant 8: 232-237, 2008
23. Reiterová J, Štekrová J, Merta M, Kotlas J, Elišáková V, Lněnička P, Korabečná M, Kohoutová M, Tesař V: Autosomal dominant polycystic kidney disease in a family with mosaicismand hypomorphic allele. BMC Nephrol 14: 59, 2013
24. Harris PC, Rossetti S: Determinants of renal disease variability in ADPKD. Adv Chronic Kidney Dis 17: 131-139, 2010
25. Bakker J, Olree M, Kaatee R, de Lange EE, Moons KG, Beutler JJ, Beek FJ: Renal volume measurements: Accuracy and repeatability of US compared with that of MR imaging. Radiology 211: 623-628, 1999
26. O'Neill WC, Robbin ML, Bae KT, Grantham JJ, Chapman AB, Guay-Woodford LM, Torres VE, King BF, Wetzel LH, Thompson PA, Miller JP: Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: The Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP). Am J Kidney Dis 46: 1058-1064, 2005
27. Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Bae KT, Baumgarten DA, Kenney PJ, King BF Jr, Glockner JF, Wetzel LH, Brummer ME, O'Neill WC, Robbin ML, Bennett WM, Klahr S, Hirschman GH, Kimmel PL, Thompson PA, Miller JP; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort: Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int 64: 1035-1045, 2003
28. Pei Y, Obaji J, Dupuis A, Paterson AD, Magistroni R, Dicks E, Parfrey P, Cramer B, Coto E, Torra R, San Millan JL, Gibson R, Breuning M, Peters D, Ravine D: Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol 20: 205-212, 2009
29. Rossetti S, Chauveau D, Walker D, Saggar-Malik A, Winearls CG, Torres VE, Harris PC: A complete mutation screen of the ADPKD genes by DHPLC. Kidney Int 61: 1588-1599, 2002
30. Grantham JJ, Cook LT, Torres VE, Bost JE, Chapman AB, Harris PC, Guay-Woodford LM, Bae KT: Determinants of renal volume in autosomal-dominant polycystic kidney disease. Kidney Int 73: 108-116, 2008
31. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612, 2009
32. Rule AD, Larson TS: Do we need another equation to estimate GFR from serum creatinine in renal allograft recipients? Nephrol Dial Transplant 23: 2427-2428, author reply 2428, 2008
33. Rutter CM, Elashoff RM: Analysis of longitudinal data: Random coefficient regression modelling. Stat Med 13: 1211-1231, 1994